SCHEMBL4497044

SCHEMBL4497044

Cc1cccc(N(c2cccc(C)c2)S(=O)(=O)c2cc(S(N)(=O)=O)cc3ccc(O)cc23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.45
TRPV1 Q8NER1 1/20 0.37
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 1/20 0.36
ESR1 P03372 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
GLA P06280 1/20 0.35
HSD17B1 P14061 3/20 0.34
HSD17B2 P37059 3/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
PKM P14618 1/20 0.34
NSD2 O96028 1/20 0.33
GLO1 Q04760 1/20 0.33
ACHE P22303 1/20 0.33
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4494785 0.87 ESR1 (0.49) PTGESLMNAESR1NPC1RAB9A
SCHEMBL4511797 0.86 PTGES (0.37) PTGESTRPV1LMNAESR1NPC1
SCHEMBL4497601 0.86 RORC (0.41) PTGESTRPV1ESR1NPC1RAB9A
SCHEMBL4500848 0.86 PTGES (0.37) PTGESTRPV1LMNAESR1NPC1
SCHEMBL4507193 0.86 CA1 (0.41) ALDH1A1HPGDHSD17B10LMNAGLA
SCHEMBL4494085 0.84 PARP1 (0.40) PTGESESR1NPC1RAB9ACA1
SCHEMBL4500899 0.84 PTGES (0.46) PTGESALDH1A1LMNAESR1NPC1
SCHEMBL4506325 0.82 PTGES (0.56) PTGESALDH1A1ESR1NPC1RAB9A
SCHEMBL4519118 0.82 PTGES (0.50) PTGESALDH1A1LMNARAB9ACA1
SCHEMBL4505853 0.81 PTGES (0.46) PTGESALDH1A1LMNAESR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090234014-A1 Naphthalene-Disulfonamides Useful for the Treatment of Inflammation BIOLIPOX AB (SE) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234014-A1 Naphthalene-Disulfonamides Useful for the Treatment of Inflammation AREG, PRSS12, CXCL8 PTGES 41/4885TRPV1 1914/4885ALDH1A1 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.